Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Thalassemia | Kisho | Kisho

Back to Thalassemia

Thalassemia — NIH Grants & Funding

Active and recent NIH-funded research on Thalassemia. Data from NIH RePORTER, last 36 months.

MONDO:0000984

NIH-funded research on Thalassemia

active grants

institutions

researchers

new in last 12 mo.

$57.1M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(16)

Basic ScienceR01Active

The Role of the MBD2-NuRD Complex in Gamma-Globin Gene Silencing

GINDER, GORDON et al.·VIRGINIA COMMONWEALTH UNIVERSITY·RICHMOND, VA

$2,965,140 (FY2025)

Thalassemia — NIH Grants & Funding

Basic Science(16)

The Role of the MBD2-NuRD Complex in Gamma-Globin Gene Silencing

Repurposing an EU Therapeutic for Hemoglobinopathies

Recombinant erythroid Kruppel-like factor fused to GATA1 upregulates globin expr

Regulation of Hemoglobin Switching

Decoding lineage-specific gene regulation across hematopoiesis

Investigating PUM1 mediated post-transcriptional regulation of human hemoglobin switching and erythropoiesis

Defining the mechanisms of hemoglobin switching and genotoxicities associated with its manipulation

Investigating the mechanisms of polycomb group protein mediated fetal hemoglobin silencing

ULK-mediated autophagy of α-globin in ß-thalassemia

The Role of Erythroferrone in Regulating Bone Metabolism in Beta-Thalassemia

Translational(2)

Development of a Clinical Hemoglobin Modulator

Targeting PGC-1a for the treatment of sickle cell disease

Clinical(2)

Pathological consequences of iron excess and hypoxia in β-thalassemia pregnancy

Iron Pathobiology in β-thalassemia Pregnancy

Gene/Cell Therapy(10)

Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias

Nonmyeloablative allogeneic PBSC in globin disorders

Preclinical and Clinical Studies in Gene Therapy for Sickle Cell Disease

Targeting ZNF410 for HbF reactivation

Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches.

DEGRADATION OF BCL11A PROTEIN FOR HbF REACTIVATION

Self-Assembling Peptide Nanoparticles for in vivo Genome Editor Delivery to Hematopoietic Stem Cells

In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease

In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle

Precise in vivo gene editing of HSPC for the treatment of genetic hematologic diseases

Other(1)

Eleventh Cooley's Anemia Symposium